RELATIONSHIP BETWEEN ANXIETY AND CARDIAC VAGAL CONTROL

焦虑与心脏迷走神经控制之间的关系

• 批准号: 6245377
• 负责人: DANIEL R MCLEOD
• 金额: $ 2.23万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-05 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245377
• 关键词: anxiety disorders; blood chemistry; cardiovascular pharmacology; clinical research; desipramine; heart function; human subject; human therapy evaluation; imipramine; neuroregulation; pharmacokinetics; psychopharmacology

The study assessed the relationship between the anticholinergic activity of imipramine, specifically changes in cardiac vagal control, and improvement in the symptoms of anxiety following treatment of generalized anxiety disorder patients with imipramine. Its purpose was to replicate previous findings from this laboratory relating anxiety reduction and cardiac vagal control and to extend those findings to include assessment of imipramine blood levels, desipramine blood levels, and anticholiriergic activity resulting from the imipramine. Fourteen patients with generalized anxiety disorder were treated for six weeks with a flexible dose regimen of imipramine. Cardiac vagal tone, measured as respiratory sinus arrythmia, and ratings from several anxiety-assessment instruments were assessed before and after treatment. During the last week of treatment, blood samples were drawn and blood levels of imipramine and desipramine were determined. The anticholinergic activity of imipramine was also determined from these blood samples. The following results were obtained: Decrease in ratings of anxiety were greatest in patients who showed the smallest decreases in cardiac vagal tone. Thus, the initial purpose of the study was achieved: our earlier findings were replicated. Similar relationships were found between anxiety reduction and both desipramine and anticholinergic levels. There was no relationship between anxiety reduction and blood imipramine levels. The strongest finding consisted of the inverse relationship between blood desipramine levels and decreases in anxiety levels following treatment (r = .82; p < .001). That is, the greater the desipramine levels were at the end of treatment, the smaller was the reduction in anxiety. Further analyses are currently underway. Results of these analyses as well as interpretation of results will follow.

该研究评估了抗胆碱能活性与 丙咪嗪，特别是心脏迷走神经控制的变化， 治疗后焦虑症状的改善 广泛性焦虑症患者丙咪嗪。 其目的是 来复制这个实验室之前的研究结果 减少和心脏迷走神经控制，并将这些发现扩展到 包括评估丙咪嗪血液水平、地昔帕明血液水平 和由丙咪嗪产生的抗胆固醇活性。 十四 广泛性焦虑症患者治疗6周， 灵活的丙咪嗪剂量方案 心脏迷走神经张力， 测量为呼吸性窦性心律失常， 焦虑评估工具在治疗前后进行评估。 在治疗的最后一周，抽取血液样本， 测定丙咪嗪和地昔帕明的水平。 的 还测定了丙咪嗪的抗胆碱能活性 血液样本 取得了以下成果： 焦虑等级最高的患者表现出最小的 心脏迷走神经张力降低。 因此，本研究的最初目的 我们的研究结果得到了证实。 类似 焦虑减少和地昔帕明之间的关系， 和抗胆碱能水平。焦虑和抑郁之间 降低和血液丙咪嗪水平。 最有力的发现包括 血液地昔帕明水平与 治疗后焦虑水平降低（r = 0.82; p <0.001）。 也就是说，地昔帕明水平越高， 治疗后，焦虑的减少幅度越小。 进一步分析 正在进行中 这些分析的结果以及 随后将对结果进行解释。